nodes	percent_of_prediction	percent_of_DWPC	metapath
Celecoxib—hematologic cancer—Methylprednisolone—multiple sclerosis	0.167	0.304	CpDpCtD
Celecoxib—ALB—multiple sclerosis	0.0938	1	CbGaD
Celecoxib—colon cancer—Betamethasone—multiple sclerosis	0.0752	0.137	CpDpCtD
Celecoxib—colon cancer—Dexamethasone—multiple sclerosis	0.0752	0.137	CpDpCtD
Celecoxib—kidney cancer—Betamethasone—multiple sclerosis	0.0544	0.0991	CpDpCtD
Celecoxib—kidney cancer—Dexamethasone—multiple sclerosis	0.0544	0.0991	CpDpCtD
Celecoxib—prostate cancer—Betamethasone—multiple sclerosis	0.0393	0.0716	CpDpCtD
Celecoxib—prostate cancer—Dexamethasone—multiple sclerosis	0.0393	0.0716	CpDpCtD
Celecoxib—PTGS2—Triamcinolone—multiple sclerosis	0.0266	0.156	CbGbCtD
Celecoxib—PTGS2—Betamethasone—multiple sclerosis	0.0228	0.134	CbGbCtD
Celecoxib—osteoarthritis—Methylprednisolone—multiple sclerosis	0.0221	0.0403	CpDpCtD
Celecoxib—osteoarthritis—Prednisone—multiple sclerosis	0.0221	0.0403	CpDpCtD
Celecoxib—ABCC4—Methotrexate—multiple sclerosis	0.0181	0.107	CbGbCtD
Celecoxib—CYP2D6—Fingolimod—multiple sclerosis	0.0169	0.0994	CbGbCtD
Celecoxib—ALB—Prednisone—multiple sclerosis	0.0134	0.0787	CbGbCtD
Celecoxib—PTGS2—Dexamethasone—multiple sclerosis	0.0133	0.0779	CbGbCtD
Celecoxib—CYP3A4—Fingolimod—multiple sclerosis	0.0108	0.0632	CbGbCtD
Celecoxib—CYP3A4—Methylprednisolone—multiple sclerosis	0.00693	0.0407	CbGbCtD
Celecoxib—ALB—Methotrexate—multiple sclerosis	0.00672	0.0395	CbGbCtD
Celecoxib—CYP3A4—Triamcinolone—multiple sclerosis	0.00525	0.0309	CbGbCtD
Celecoxib—CYP3A4—Mitoxantrone—multiple sclerosis	0.00506	0.0297	CbGbCtD
Celecoxib—CYP2C9—Dexamethasone—multiple sclerosis	0.00451	0.0265	CbGbCtD
Celecoxib—CYP3A4—Betamethasone—multiple sclerosis	0.00451	0.0265	CbGbCtD
Celecoxib—CYP3A4—Prednisolone—multiple sclerosis	0.00445	0.0261	CbGbCtD
Celecoxib—CYP3A4—Prednisone—multiple sclerosis	0.0042	0.0247	CbGbCtD
Celecoxib—CYP2D6—Dexamethasone—multiple sclerosis	0.00412	0.0242	CbGbCtD
Celecoxib—CYP3A4—Dexamethasone—multiple sclerosis	0.00262	0.0154	CbGbCtD
Celecoxib—PDPK1—retina—multiple sclerosis	0.00142	0.0625	CbGeAlD
Celecoxib—PDPK1—medulla oblongata—multiple sclerosis	0.00103	0.0452	CbGeAlD
Celecoxib—PTGS2—leg—multiple sclerosis	0.000974	0.0427	CbGeAlD
Celecoxib—PDPK1—midbrain—multiple sclerosis	0.000941	0.0413	CbGeAlD
Celecoxib—PDPK1—spinal cord—multiple sclerosis	0.000918	0.0403	CbGeAlD
Celecoxib—CA4—nerve—multiple sclerosis	0.000864	0.0379	CbGeAlD
Celecoxib—MAPK14—brainstem—multiple sclerosis	0.00079	0.0347	CbGeAlD
Celecoxib—PDPK1—nervous system—multiple sclerosis	0.000774	0.0339	CbGeAlD
Celecoxib—PDPK1—central nervous system—multiple sclerosis	0.000745	0.0327	CbGeAlD
Celecoxib—PDPK1—cerebellum—multiple sclerosis	0.000728	0.0319	CbGeAlD
Celecoxib—PDPK1—brain—multiple sclerosis	0.000591	0.0259	CbGeAlD
Celecoxib—CA14—medulla oblongata—multiple sclerosis	0.000536	0.0235	CbGeAlD
Celecoxib—MAPK14—spinal cord—multiple sclerosis	0.000491	0.0215	CbGeAlD
Celecoxib—CA14—midbrain—multiple sclerosis	0.00049	0.0215	CbGeAlD
Celecoxib—CA14—spinal cord—multiple sclerosis	0.000478	0.021	CbGeAlD
Celecoxib—MAPK14—nervous system—multiple sclerosis	0.000414	0.0182	CbGeAlD
Celecoxib—CA9—cerebellum—multiple sclerosis	0.000399	0.0175	CbGeAlD
Celecoxib—MAPK14—central nervous system—multiple sclerosis	0.000398	0.0175	CbGeAlD
Celecoxib—MAPK14—cerebellum—multiple sclerosis	0.000389	0.0171	CbGeAlD
Celecoxib—CA14—cerebellum—multiple sclerosis	0.000379	0.0166	CbGeAlD
Celecoxib—CA4—brainstem—multiple sclerosis	0.000371	0.0163	CbGeAlD
Celecoxib—MAPK14—brain—multiple sclerosis	0.000316	0.0139	CbGeAlD
Celecoxib—CA12—nervous system—multiple sclerosis	0.000314	0.0138	CbGeAlD
Celecoxib—CA14—brain—multiple sclerosis	0.000308	0.0135	CbGeAlD
Celecoxib—CA2—brainstem—multiple sclerosis	0.000308	0.0135	CbGeAlD
Celecoxib—CA12—central nervous system—multiple sclerosis	0.000302	0.0133	CbGeAlD
Celecoxib—CA2—retina—multiple sclerosis	0.000297	0.013	CbGeAlD
Celecoxib—ORM1—spinal cord—multiple sclerosis	0.000296	0.013	CbGeAlD
Celecoxib—CA5B—nervous system—multiple sclerosis	0.000282	0.0124	CbGeAlD
Celecoxib—CA5B—central nervous system—multiple sclerosis	0.000271	0.0119	CbGeAlD
Celecoxib—PTGS2—Fluocinonide—Methylprednisolone—multiple sclerosis	0.000263	0.159	CbGdCrCtD
Celecoxib—PTGS2—Fluocinonide—Betamethasone—multiple sclerosis	0.000259	0.156	CbGdCrCtD
Celecoxib—PTGS2—Fluocinonide—Dexamethasone—multiple sclerosis	0.000259	0.156	CbGdCrCtD
Celecoxib—CA4—medulla oblongata—multiple sclerosis	0.000259	0.0114	CbGeAlD
Celecoxib—PTGS2—Fluocinonide—Triamcinolone—multiple sclerosis	0.000253	0.153	CbGdCrCtD
Celecoxib—ORM1—nervous system—multiple sclerosis	0.000249	0.0109	CbGeAlD
Celecoxib—CA12—brain—multiple sclerosis	0.00024	0.0105	CbGeAlD
Celecoxib—ORM1—central nervous system—multiple sclerosis	0.00024	0.0105	CbGeAlD
Celecoxib—CA4—midbrain—multiple sclerosis	0.000236	0.0104	CbGeAlD
Celecoxib—CA4—spinal cord—multiple sclerosis	0.000231	0.0101	CbGeAlD
Celecoxib—CA5B—brain—multiple sclerosis	0.000215	0.00944	CbGeAlD
Celecoxib—CA2—medulla oblongata—multiple sclerosis	0.000215	0.00941	CbGeAlD
Celecoxib—ABCC4—nervous system—multiple sclerosis	0.000211	0.00928	CbGeAlD
Celecoxib—ABCC4—central nervous system—multiple sclerosis	0.000204	0.00893	CbGeAlD
Celecoxib—CA2—midbrain—multiple sclerosis	0.000196	0.0086	CbGeAlD
Celecoxib—CYP2D6—brainstem—multiple sclerosis	0.000195	0.00857	CbGeAlD
Celecoxib—CA4—nervous system—multiple sclerosis	0.000194	0.00853	CbGeAlD
Celecoxib—CA2—spinal cord—multiple sclerosis	0.000191	0.00839	CbGeAlD
Celecoxib—CA4—central nervous system—multiple sclerosis	0.000187	0.00821	CbGeAlD
Celecoxib—CA4—cerebellum—multiple sclerosis	0.000183	0.00803	CbGeAlD
Celecoxib—ALB—brain—multiple sclerosis	0.000167	0.00733	CbGeAlD
Celecoxib—ABCC4—brain—multiple sclerosis	0.000162	0.00709	CbGeAlD
Celecoxib—CA2—nervous system—multiple sclerosis	0.000161	0.00707	CbGeAlD
Celecoxib—PTGS2—Fluticasone Propionate—Methylprednisolone—multiple sclerosis	0.000159	0.0958	CbGdCrCtD
Celecoxib—PTGS2—medulla oblongata—multiple sclerosis	0.000158	0.00695	CbGeAlD
Celecoxib—PTGS2—Fluticasone Propionate—Betamethasone—multiple sclerosis	0.000156	0.0943	CbGdCrCtD
Celecoxib—PTGS2—Fluticasone Propionate—Dexamethasone—multiple sclerosis	0.000156	0.0943	CbGdCrCtD
Celecoxib—CA2—central nervous system—multiple sclerosis	0.000155	0.00681	CbGeAlD
Celecoxib—PTGS2—Fluticasone Propionate—Triamcinolone—multiple sclerosis	0.000153	0.0921	CbGdCrCtD
Celecoxib—CA2—cerebellum—multiple sclerosis	0.000152	0.00665	CbGeAlD
Celecoxib—CA4—brain—multiple sclerosis	0.000149	0.00652	CbGeAlD
Celecoxib—PTGS2—midbrain—multiple sclerosis	0.000145	0.00635	CbGeAlD
Celecoxib—PTGS2—spinal cord—multiple sclerosis	0.000141	0.0062	CbGeAlD
Celecoxib—CA2—brain—multiple sclerosis	0.000123	0.00541	CbGeAlD
Celecoxib—PTGS2—nervous system—multiple sclerosis	0.000119	0.00522	CbGeAlD
Celecoxib—PTGS2—central nervous system—multiple sclerosis	0.000115	0.00503	CbGeAlD
Celecoxib—PTGS2—cerebellum—multiple sclerosis	0.000112	0.00491	CbGeAlD
Celecoxib—CYP3A4—nervous system—multiple sclerosis	0.000104	0.00456	CbGeAlD
Celecoxib—CYP2D6—nervous system—multiple sclerosis	0.000102	0.00449	CbGeAlD
Celecoxib—CYP3A4—central nervous system—multiple sclerosis	0.0001	0.00439	CbGeAlD
Celecoxib—CYP2D6—central nervous system—multiple sclerosis	9.85e-05	0.00432	CbGeAlD
Celecoxib—CYP2D6—cerebellum—multiple sclerosis	9.63e-05	0.00422	CbGeAlD
Celecoxib—PTGS2—brain—multiple sclerosis	9.1e-05	0.00399	CbGeAlD
Celecoxib—CYP2D6—brain—multiple sclerosis	7.82e-05	0.00343	CbGeAlD
Celecoxib—Confusional state—Methylprednisolone—multiple sclerosis	4.88e-05	0.000546	CcSEcCtD
Celecoxib—Immune system disorder—Prednisone—multiple sclerosis	4.88e-05	0.000545	CcSEcCtD
Celecoxib—Anaphylactic shock—Triamcinolone—multiple sclerosis	4.85e-05	0.000543	CcSEcCtD
Celecoxib—Oedema—Triamcinolone—multiple sclerosis	4.85e-05	0.000543	CcSEcCtD
Celecoxib—Vertigo—Betamethasone—multiple sclerosis	4.85e-05	0.000542	CcSEcCtD
Celecoxib—Vertigo—Dexamethasone—multiple sclerosis	4.85e-05	0.000542	CcSEcCtD
Celecoxib—Anaphylactic shock—Methylprednisolone—multiple sclerosis	4.84e-05	0.000542	CcSEcCtD
Celecoxib—Syncope—Betamethasone—multiple sclerosis	4.84e-05	0.000541	CcSEcCtD
Celecoxib—Syncope—Dexamethasone—multiple sclerosis	4.84e-05	0.000541	CcSEcCtD
Celecoxib—Arrhythmia—Prednisone—multiple sclerosis	4.82e-05	0.000539	CcSEcCtD
Celecoxib—Infection—Triamcinolone—multiple sclerosis	4.82e-05	0.000539	CcSEcCtD
Celecoxib—Infection—Methylprednisolone—multiple sclerosis	4.81e-05	0.000538	CcSEcCtD
Celecoxib—Haematuria—Methotrexate—multiple sclerosis	4.79e-05	0.000536	CcSEcCtD
Celecoxib—Shock—Triamcinolone—multiple sclerosis	4.78e-05	0.000534	CcSEcCtD
Celecoxib—Insomnia—Prednisolone—multiple sclerosis	4.77e-05	0.000534	CcSEcCtD
Celecoxib—Alopecia—Prednisone—multiple sclerosis	4.77e-05	0.000534	CcSEcCtD
Celecoxib—Shock—Methylprednisolone—multiple sclerosis	4.77e-05	0.000533	CcSEcCtD
Celecoxib—Hepatobiliary disease—Methotrexate—multiple sclerosis	4.75e-05	0.000532	CcSEcCtD
Celecoxib—Nervous system disorder—Methylprednisolone—multiple sclerosis	4.75e-05	0.000531	CcSEcCtD
Celecoxib—Loss of consciousness—Dexamethasone—multiple sclerosis	4.74e-05	0.00053	CcSEcCtD
Celecoxib—Loss of consciousness—Betamethasone—multiple sclerosis	4.74e-05	0.00053	CcSEcCtD
Celecoxib—Epistaxis—Methotrexate—multiple sclerosis	4.74e-05	0.00053	CcSEcCtD
Celecoxib—Hypersensitivity—Mitoxantrone—multiple sclerosis	4.74e-05	0.00053	CcSEcCtD
Celecoxib—Paraesthesia—Prednisolone—multiple sclerosis	4.74e-05	0.00053	CcSEcCtD
Celecoxib—Tachycardia—Triamcinolone—multiple sclerosis	4.74e-05	0.00053	CcSEcCtD
Celecoxib—Mental disorder—Prednisone—multiple sclerosis	4.73e-05	0.000529	CcSEcCtD
Celecoxib—Nausea—Azathioprine—multiple sclerosis	4.73e-05	0.000529	CcSEcCtD
Celecoxib—Tachycardia—Methylprednisolone—multiple sclerosis	4.73e-05	0.000529	CcSEcCtD
Celecoxib—Skin disorder—Methylprednisolone—multiple sclerosis	4.7e-05	0.000526	CcSEcCtD
Celecoxib—Hyperhidrosis—Triamcinolone—multiple sclerosis	4.69e-05	0.000525	CcSEcCtD
Celecoxib—Agranulocytosis—Methotrexate—multiple sclerosis	4.69e-05	0.000525	CcSEcCtD
Celecoxib—Hyperhidrosis—Methylprednisolone—multiple sclerosis	4.68e-05	0.000524	CcSEcCtD
Celecoxib—Hypertension—Betamethasone—multiple sclerosis	4.66e-05	0.000521	CcSEcCtD
Celecoxib—Hypertension—Dexamethasone—multiple sclerosis	4.66e-05	0.000521	CcSEcCtD
Celecoxib—Asthenia—Mitoxantrone—multiple sclerosis	4.62e-05	0.000516	CcSEcCtD
Celecoxib—Myalgia—Betamethasone—multiple sclerosis	4.59e-05	0.000514	CcSEcCtD
Celecoxib—Myalgia—Dexamethasone—multiple sclerosis	4.59e-05	0.000514	CcSEcCtD
Celecoxib—Anxiety—Dexamethasone—multiple sclerosis	4.58e-05	0.000512	CcSEcCtD
Celecoxib—Anxiety—Betamethasone—multiple sclerosis	4.58e-05	0.000512	CcSEcCtD
Celecoxib—Haemoglobin—Methotrexate—multiple sclerosis	4.53e-05	0.000507	CcSEcCtD
Celecoxib—Haemorrhage—Methotrexate—multiple sclerosis	4.51e-05	0.000505	CcSEcCtD
Celecoxib—Hepatitis—Methotrexate—multiple sclerosis	4.51e-05	0.000505	CcSEcCtD
Celecoxib—Pharyngitis—Methotrexate—multiple sclerosis	4.48e-05	0.000501	CcSEcCtD
Celecoxib—Urinary tract disorder—Methotrexate—multiple sclerosis	4.46e-05	0.000498	CcSEcCtD
Celecoxib—Vision blurred—Prednisone—multiple sclerosis	4.43e-05	0.000495	CcSEcCtD
Celecoxib—Urethral disorder—Methotrexate—multiple sclerosis	4.42e-05	0.000495	CcSEcCtD
Celecoxib—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	4.42e-05	0.000495	CcSEcCtD
Celecoxib—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	4.41e-05	0.000494	CcSEcCtD
Celecoxib—Oedema—Dexamethasone—multiple sclerosis	4.4e-05	0.000493	CcSEcCtD
Celecoxib—Anaphylactic shock—Betamethasone—multiple sclerosis	4.4e-05	0.000493	CcSEcCtD
Celecoxib—Anaphylactic shock—Dexamethasone—multiple sclerosis	4.4e-05	0.000493	CcSEcCtD
Celecoxib—Oedema—Betamethasone—multiple sclerosis	4.4e-05	0.000493	CcSEcCtD
Celecoxib—Diarrhoea—Mitoxantrone—multiple sclerosis	4.4e-05	0.000492	CcSEcCtD
Celecoxib—Insomnia—Triamcinolone—multiple sclerosis	4.39e-05	0.000491	CcSEcCtD
Celecoxib—Insomnia—Methylprednisolone—multiple sclerosis	4.38e-05	0.00049	CcSEcCtD
Celecoxib—Infection—Dexamethasone—multiple sclerosis	4.38e-05	0.000489	CcSEcCtD
Celecoxib—Infection—Betamethasone—multiple sclerosis	4.38e-05	0.000489	CcSEcCtD
Celecoxib—Paraesthesia—Triamcinolone—multiple sclerosis	4.36e-05	0.000487	CcSEcCtD
Celecoxib—Feeling abnormal—Prednisolone—multiple sclerosis	4.35e-05	0.000486	CcSEcCtD
Celecoxib—Paraesthesia—Methylprednisolone—multiple sclerosis	4.35e-05	0.000486	CcSEcCtD
Celecoxib—Anaemia—Prednisone—multiple sclerosis	4.34e-05	0.000486	CcSEcCtD
Celecoxib—Shock—Betamethasone—multiple sclerosis	4.33e-05	0.000485	CcSEcCtD
Celecoxib—Shock—Dexamethasone—multiple sclerosis	4.33e-05	0.000485	CcSEcCtD
Celecoxib—Dyspnoea—Triamcinolone—multiple sclerosis	4.33e-05	0.000484	CcSEcCtD
Celecoxib—Nervous system disorder—Dexamethasone—multiple sclerosis	4.32e-05	0.000483	CcSEcCtD
Celecoxib—Nervous system disorder—Betamethasone—multiple sclerosis	4.32e-05	0.000483	CcSEcCtD
Celecoxib—Thrombocytopenia—Betamethasone—multiple sclerosis	4.31e-05	0.000482	CcSEcCtD
Celecoxib—Thrombocytopenia—Dexamethasone—multiple sclerosis	4.31e-05	0.000482	CcSEcCtD
Celecoxib—Tachycardia—Dexamethasone—multiple sclerosis	4.3e-05	0.000481	CcSEcCtD
Celecoxib—Tachycardia—Betamethasone—multiple sclerosis	4.3e-05	0.000481	CcSEcCtD
Celecoxib—Angioedema—Prednisone—multiple sclerosis	4.29e-05	0.00048	CcSEcCtD
Celecoxib—Dyspepsia—Triamcinolone—multiple sclerosis	4.27e-05	0.000478	CcSEcCtD
Celecoxib—Erythema multiforme—Methotrexate—multiple sclerosis	4.27e-05	0.000477	CcSEcCtD
Celecoxib—Dyspepsia—Methylprednisolone—multiple sclerosis	4.26e-05	0.000477	CcSEcCtD
Celecoxib—Hyperhidrosis—Dexamethasone—multiple sclerosis	4.26e-05	0.000476	CcSEcCtD
Celecoxib—Hyperhidrosis—Betamethasone—multiple sclerosis	4.26e-05	0.000476	CcSEcCtD
Celecoxib—Vertigo—Prednisone—multiple sclerosis	4.22e-05	0.000472	CcSEcCtD
Celecoxib—Eye disorder—Methotrexate—multiple sclerosis	4.22e-05	0.000472	CcSEcCtD
Celecoxib—Syncope—Prednisone—multiple sclerosis	4.21e-05	0.000471	CcSEcCtD
Celecoxib—Tinnitus—Methotrexate—multiple sclerosis	4.21e-05	0.00047	CcSEcCtD
Celecoxib—Anorexia—Betamethasone—multiple sclerosis	4.2e-05	0.00047	CcSEcCtD
Celecoxib—Anorexia—Dexamethasone—multiple sclerosis	4.2e-05	0.00047	CcSEcCtD
Celecoxib—Urticaria—Prednisolone—multiple sclerosis	4.19e-05	0.000469	CcSEcCtD
Celecoxib—Cardiac disorder—Methotrexate—multiple sclerosis	4.19e-05	0.000468	CcSEcCtD
Celecoxib—Fatigue—Triamcinolone—multiple sclerosis	4.19e-05	0.000468	CcSEcCtD
Celecoxib—Fatigue—Methylprednisolone—multiple sclerosis	4.18e-05	0.000467	CcSEcCtD
Celecoxib—Loss of consciousness—Prednisone—multiple sclerosis	4.13e-05	0.000462	CcSEcCtD
Celecoxib—Angiopathy—Methotrexate—multiple sclerosis	4.09e-05	0.000458	CcSEcCtD
Celecoxib—Vomiting—Mitoxantrone—multiple sclerosis	4.09e-05	0.000458	CcSEcCtD
Celecoxib—Immune system disorder—Methotrexate—multiple sclerosis	4.08e-05	0.000456	CcSEcCtD
Celecoxib—Mediastinal disorder—Methotrexate—multiple sclerosis	4.07e-05	0.000455	CcSEcCtD
Celecoxib—Hypertension—Prednisone—multiple sclerosis	4.06e-05	0.000454	CcSEcCtD
Celecoxib—Rash—Mitoxantrone—multiple sclerosis	4.06e-05	0.000454	CcSEcCtD
Celecoxib—Dermatitis—Mitoxantrone—multiple sclerosis	4.05e-05	0.000453	CcSEcCtD
Celecoxib—Headache—Mitoxantrone—multiple sclerosis	4.03e-05	0.000451	CcSEcCtD
Celecoxib—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	4.01e-05	0.000449	CcSEcCtD
Celecoxib—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	4.01e-05	0.000449	CcSEcCtD
Celecoxib—Arthralgia—Prednisone—multiple sclerosis	4e-05	0.000447	CcSEcCtD
Celecoxib—Myalgia—Prednisone—multiple sclerosis	4e-05	0.000447	CcSEcCtD
Celecoxib—Feeling abnormal—Triamcinolone—multiple sclerosis	4e-05	0.000447	CcSEcCtD
Celecoxib—Feeling abnormal—Methylprednisolone—multiple sclerosis	3.99e-05	0.000446	CcSEcCtD
Celecoxib—Anxiety—Prednisone—multiple sclerosis	3.99e-05	0.000446	CcSEcCtD
Celecoxib—Alopecia—Methotrexate—multiple sclerosis	3.99e-05	0.000446	CcSEcCtD
Celecoxib—Insomnia—Dexamethasone—multiple sclerosis	3.98e-05	0.000446	CcSEcCtD
Celecoxib—Insomnia—Betamethasone—multiple sclerosis	3.98e-05	0.000446	CcSEcCtD
Celecoxib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	3.97e-05	0.000444	CcSEcCtD
Celecoxib—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	3.96e-05	0.000443	CcSEcCtD
Celecoxib—Paraesthesia—Dexamethasone—multiple sclerosis	3.95e-05	0.000442	CcSEcCtD
Celecoxib—Paraesthesia—Betamethasone—multiple sclerosis	3.95e-05	0.000442	CcSEcCtD
Celecoxib—Mental disorder—Methotrexate—multiple sclerosis	3.95e-05	0.000442	CcSEcCtD
Celecoxib—Hypersensitivity—Prednisolone—multiple sclerosis	3.89e-05	0.000435	CcSEcCtD
Celecoxib—Dyspepsia—Dexamethasone—multiple sclerosis	3.88e-05	0.000434	CcSEcCtD
Celecoxib—Dyspepsia—Betamethasone—multiple sclerosis	3.88e-05	0.000434	CcSEcCtD
Celecoxib—Urticaria—Triamcinolone—multiple sclerosis	3.86e-05	0.000431	CcSEcCtD
Celecoxib—Urticaria—Methylprednisolone—multiple sclerosis	3.85e-05	0.00043	CcSEcCtD
Celecoxib—Dysgeusia—Methotrexate—multiple sclerosis	3.85e-05	0.00043	CcSEcCtD
Celecoxib—Body temperature increased—Triamcinolone—multiple sclerosis	3.84e-05	0.000429	CcSEcCtD
Celecoxib—Anaphylactic shock—Prednisone—multiple sclerosis	3.84e-05	0.000429	CcSEcCtD
Celecoxib—Oedema—Prednisone—multiple sclerosis	3.84e-05	0.000429	CcSEcCtD
Celecoxib—Abdominal pain—Methylprednisolone—multiple sclerosis	3.83e-05	0.000428	CcSEcCtD
Celecoxib—Decreased appetite—Betamethasone—multiple sclerosis	3.83e-05	0.000428	CcSEcCtD
Celecoxib—Decreased appetite—Dexamethasone—multiple sclerosis	3.83e-05	0.000428	CcSEcCtD
Celecoxib—Nausea—Mitoxantrone—multiple sclerosis	3.82e-05	0.000427	CcSEcCtD
Celecoxib—Infection—Prednisone—multiple sclerosis	3.81e-05	0.000426	CcSEcCtD
Celecoxib—Gastrointestinal disorder—Betamethasone—multiple sclerosis	3.8e-05	0.000425	CcSEcCtD
Celecoxib—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	3.8e-05	0.000425	CcSEcCtD
Celecoxib—Back pain—Methotrexate—multiple sclerosis	3.8e-05	0.000425	CcSEcCtD
Celecoxib—Fatigue—Betamethasone—multiple sclerosis	3.8e-05	0.000425	CcSEcCtD
Celecoxib—Fatigue—Dexamethasone—multiple sclerosis	3.8e-05	0.000425	CcSEcCtD
Celecoxib—Shock—Prednisone—multiple sclerosis	3.77e-05	0.000422	CcSEcCtD
Celecoxib—Nervous system disorder—Prednisone—multiple sclerosis	3.76e-05	0.000421	CcSEcCtD
Celecoxib—Tachycardia—Prednisone—multiple sclerosis	3.74e-05	0.000419	CcSEcCtD
Celecoxib—Skin disorder—Prednisone—multiple sclerosis	3.73e-05	0.000417	CcSEcCtD
Celecoxib—Hyperhidrosis—Prednisone—multiple sclerosis	3.71e-05	0.000415	CcSEcCtD
Celecoxib—Vision blurred—Methotrexate—multiple sclerosis	3.7e-05	0.000414	CcSEcCtD
Celecoxib—Anorexia—Prednisone—multiple sclerosis	3.66e-05	0.000409	CcSEcCtD
Celecoxib—Anaemia—Methotrexate—multiple sclerosis	3.63e-05	0.000406	CcSEcCtD
Celecoxib—Feeling abnormal—Betamethasone—multiple sclerosis	3.63e-05	0.000406	CcSEcCtD
Celecoxib—Feeling abnormal—Dexamethasone—multiple sclerosis	3.63e-05	0.000406	CcSEcCtD
Celecoxib—Gastrointestinal pain—Dexamethasone—multiple sclerosis	3.6e-05	0.000403	CcSEcCtD
Celecoxib—Gastrointestinal pain—Betamethasone—multiple sclerosis	3.6e-05	0.000403	CcSEcCtD
Celecoxib—Hypersensitivity—Triamcinolone—multiple sclerosis	3.58e-05	0.0004	CcSEcCtD
Celecoxib—Hypersensitivity—Methylprednisolone—multiple sclerosis	3.57e-05	0.000399	CcSEcCtD
Celecoxib—Vertigo—Methotrexate—multiple sclerosis	3.53e-05	0.000395	CcSEcCtD
Celecoxib—Leukopenia—Methotrexate—multiple sclerosis	3.52e-05	0.000393	CcSEcCtD
Celecoxib—Urticaria—Dexamethasone—multiple sclerosis	3.5e-05	0.000391	CcSEcCtD
Celecoxib—Urticaria—Betamethasone—multiple sclerosis	3.5e-05	0.000391	CcSEcCtD
Celecoxib—Musculoskeletal discomfort—Prednisone—multiple sclerosis	3.49e-05	0.000391	CcSEcCtD
Celecoxib—Dizziness—Prednisolone—multiple sclerosis	3.49e-05	0.00039	CcSEcCtD
Celecoxib—Asthenia—Triamcinolone—multiple sclerosis	3.48e-05	0.00039	CcSEcCtD
Celecoxib—Abdominal pain—Betamethasone—multiple sclerosis	3.48e-05	0.000389	CcSEcCtD
Celecoxib—Body temperature increased—Betamethasone—multiple sclerosis	3.48e-05	0.000389	CcSEcCtD
Celecoxib—Abdominal pain—Dexamethasone—multiple sclerosis	3.48e-05	0.000389	CcSEcCtD
Celecoxib—Body temperature increased—Dexamethasone—multiple sclerosis	3.48e-05	0.000389	CcSEcCtD
Celecoxib—Asthenia—Methylprednisolone—multiple sclerosis	3.47e-05	0.000389	CcSEcCtD
Celecoxib—Insomnia—Prednisone—multiple sclerosis	3.47e-05	0.000388	CcSEcCtD
Celecoxib—Paraesthesia—Prednisone—multiple sclerosis	3.44e-05	0.000385	CcSEcCtD
Celecoxib—Pruritus—Triamcinolone—multiple sclerosis	3.43e-05	0.000384	CcSEcCtD
Celecoxib—Cough—Methotrexate—multiple sclerosis	3.43e-05	0.000383	CcSEcCtD
Celecoxib—Pruritus—Methylprednisolone—multiple sclerosis	3.43e-05	0.000383	CcSEcCtD
Celecoxib—Dyspepsia—Prednisone—multiple sclerosis	3.38e-05	0.000378	CcSEcCtD
Celecoxib—Arthralgia—Methotrexate—multiple sclerosis	3.34e-05	0.000374	CcSEcCtD
Celecoxib—Myalgia—Methotrexate—multiple sclerosis	3.34e-05	0.000374	CcSEcCtD
Celecoxib—Chest pain—Methotrexate—multiple sclerosis	3.34e-05	0.000374	CcSEcCtD
Celecoxib—Decreased appetite—Prednisone—multiple sclerosis	3.33e-05	0.000373	CcSEcCtD
Celecoxib—Rash—Prednisolone—multiple sclerosis	3.33e-05	0.000372	CcSEcCtD
Celecoxib—Dermatitis—Prednisolone—multiple sclerosis	3.33e-05	0.000372	CcSEcCtD
Celecoxib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	3.32e-05	0.000371	CcSEcCtD
Celecoxib—Diarrhoea—Methylprednisolone—multiple sclerosis	3.31e-05	0.000371	CcSEcCtD
Celecoxib—Fatigue—Prednisone—multiple sclerosis	3.31e-05	0.00037	CcSEcCtD
Celecoxib—Headache—Prednisolone—multiple sclerosis	3.31e-05	0.00037	CcSEcCtD
Celecoxib—Constipation—Prednisone—multiple sclerosis	3.28e-05	0.000367	CcSEcCtD
Celecoxib—Confusional state—Methotrexate—multiple sclerosis	3.23e-05	0.000361	CcSEcCtD
Celecoxib—Dizziness—Triamcinolone—multiple sclerosis	3.21e-05	0.000359	CcSEcCtD
Celecoxib—Anaphylactic shock—Methotrexate—multiple sclerosis	3.21e-05	0.000359	CcSEcCtD
Celecoxib—Dizziness—Methylprednisolone—multiple sclerosis	3.2e-05	0.000358	CcSEcCtD
Celecoxib—Infection—Methotrexate—multiple sclerosis	3.18e-05	0.000356	CcSEcCtD
Celecoxib—Feeling abnormal—Prednisone—multiple sclerosis	3.16e-05	0.000354	CcSEcCtD
Celecoxib—Asthenia—Dexamethasone—multiple sclerosis	3.16e-05	0.000353	CcSEcCtD
Celecoxib—Asthenia—Betamethasone—multiple sclerosis	3.16e-05	0.000353	CcSEcCtD
Celecoxib—Nervous system disorder—Methotrexate—multiple sclerosis	3.14e-05	0.000352	CcSEcCtD
Celecoxib—Thrombocytopenia—Methotrexate—multiple sclerosis	3.14e-05	0.000351	CcSEcCtD
Celecoxib—Gastrointestinal pain—Prednisone—multiple sclerosis	3.14e-05	0.000351	CcSEcCtD
Celecoxib—Nausea—Prednisolone—multiple sclerosis	3.14e-05	0.000351	CcSEcCtD
Celecoxib—Pruritus—Dexamethasone—multiple sclerosis	3.12e-05	0.000349	CcSEcCtD
Celecoxib—Pruritus—Betamethasone—multiple sclerosis	3.12e-05	0.000349	CcSEcCtD
Celecoxib—Skin disorder—Methotrexate—multiple sclerosis	3.11e-05	0.000348	CcSEcCtD
Celecoxib—Hyperhidrosis—Methotrexate—multiple sclerosis	3.1e-05	0.000347	CcSEcCtD
Celecoxib—Vomiting—Triamcinolone—multiple sclerosis	3.09e-05	0.000345	CcSEcCtD
Celecoxib—Vomiting—Methylprednisolone—multiple sclerosis	3.08e-05	0.000344	CcSEcCtD
Celecoxib—Rash—Triamcinolone—multiple sclerosis	3.06e-05	0.000342	CcSEcCtD
Celecoxib—Dermatitis—Triamcinolone—multiple sclerosis	3.06e-05	0.000342	CcSEcCtD
Celecoxib—Anorexia—Methotrexate—multiple sclerosis	3.06e-05	0.000342	CcSEcCtD
Celecoxib—Rash—Methylprednisolone—multiple sclerosis	3.05e-05	0.000342	CcSEcCtD
Celecoxib—Dermatitis—Methylprednisolone—multiple sclerosis	3.05e-05	0.000341	CcSEcCtD
Celecoxib—Urticaria—Prednisone—multiple sclerosis	3.05e-05	0.000341	CcSEcCtD
Celecoxib—Headache—Triamcinolone—multiple sclerosis	3.04e-05	0.00034	CcSEcCtD
Celecoxib—Headache—Methylprednisolone—multiple sclerosis	3.03e-05	0.000339	CcSEcCtD
Celecoxib—Abdominal pain—Prednisone—multiple sclerosis	3.03e-05	0.000339	CcSEcCtD
Celecoxib—Body temperature increased—Prednisone—multiple sclerosis	3.03e-05	0.000339	CcSEcCtD
Celecoxib—Diarrhoea—Betamethasone—multiple sclerosis	3.01e-05	0.000337	CcSEcCtD
Celecoxib—Diarrhoea—Dexamethasone—multiple sclerosis	3.01e-05	0.000337	CcSEcCtD
Celecoxib—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	2.92e-05	0.000327	CcSEcCtD
Celecoxib—Dizziness—Betamethasone—multiple sclerosis	2.91e-05	0.000326	CcSEcCtD
Celecoxib—Dizziness—Dexamethasone—multiple sclerosis	2.91e-05	0.000326	CcSEcCtD
Celecoxib—Insomnia—Methotrexate—multiple sclerosis	2.9e-05	0.000324	CcSEcCtD
Celecoxib—Nausea—Triamcinolone—multiple sclerosis	2.88e-05	0.000322	CcSEcCtD
Celecoxib—Paraesthesia—Methotrexate—multiple sclerosis	2.88e-05	0.000322	CcSEcCtD
Celecoxib—Nausea—Methylprednisolone—multiple sclerosis	2.88e-05	0.000322	CcSEcCtD
Celecoxib—Dyspnoea—Methotrexate—multiple sclerosis	2.86e-05	0.00032	CcSEcCtD
Celecoxib—Somnolence—Methotrexate—multiple sclerosis	2.85e-05	0.000319	CcSEcCtD
Celecoxib—Hypersensitivity—Prednisone—multiple sclerosis	2.83e-05	0.000316	CcSEcCtD
Celecoxib—Dyspepsia—Methotrexate—multiple sclerosis	2.82e-05	0.000316	CcSEcCtD
Celecoxib—Vomiting—Betamethasone—multiple sclerosis	2.8e-05	0.000313	CcSEcCtD
Celecoxib—Vomiting—Dexamethasone—multiple sclerosis	2.8e-05	0.000313	CcSEcCtD
Celecoxib—Decreased appetite—Methotrexate—multiple sclerosis	2.79e-05	0.000312	CcSEcCtD
Celecoxib—Rash—Betamethasone—multiple sclerosis	2.78e-05	0.000311	CcSEcCtD
Celecoxib—Rash—Dexamethasone—multiple sclerosis	2.78e-05	0.000311	CcSEcCtD
Celecoxib—Dermatitis—Betamethasone—multiple sclerosis	2.77e-05	0.00031	CcSEcCtD
Celecoxib—Dermatitis—Dexamethasone—multiple sclerosis	2.77e-05	0.00031	CcSEcCtD
Celecoxib—Gastrointestinal disorder—Methotrexate—multiple sclerosis	2.77e-05	0.00031	CcSEcCtD
Celecoxib—Fatigue—Methotrexate—multiple sclerosis	2.76e-05	0.000309	CcSEcCtD
Celecoxib—Headache—Dexamethasone—multiple sclerosis	2.76e-05	0.000309	CcSEcCtD
Celecoxib—Headache—Betamethasone—multiple sclerosis	2.76e-05	0.000309	CcSEcCtD
Celecoxib—Asthenia—Prednisone—multiple sclerosis	2.75e-05	0.000308	CcSEcCtD
Celecoxib—Pruritus—Prednisone—multiple sclerosis	2.71e-05	0.000304	CcSEcCtD
Celecoxib—Feeling abnormal—Methotrexate—multiple sclerosis	2.64e-05	0.000295	CcSEcCtD
Celecoxib—Diarrhoea—Prednisone—multiple sclerosis	2.62e-05	0.000294	CcSEcCtD
Celecoxib—Gastrointestinal pain—Methotrexate—multiple sclerosis	2.62e-05	0.000293	CcSEcCtD
Celecoxib—Nausea—Dexamethasone—multiple sclerosis	2.62e-05	0.000293	CcSEcCtD
Celecoxib—Nausea—Betamethasone—multiple sclerosis	2.62e-05	0.000293	CcSEcCtD
Celecoxib—Urticaria—Methotrexate—multiple sclerosis	2.55e-05	0.000285	CcSEcCtD
Celecoxib—Dizziness—Prednisone—multiple sclerosis	2.54e-05	0.000284	CcSEcCtD
Celecoxib—Body temperature increased—Methotrexate—multiple sclerosis	2.53e-05	0.000283	CcSEcCtD
Celecoxib—Abdominal pain—Methotrexate—multiple sclerosis	2.53e-05	0.000283	CcSEcCtD
Celecoxib—Vomiting—Prednisone—multiple sclerosis	2.44e-05	0.000273	CcSEcCtD
Celecoxib—Rash—Prednisone—multiple sclerosis	2.42e-05	0.00027	CcSEcCtD
Celecoxib—Dermatitis—Prednisone—multiple sclerosis	2.42e-05	0.00027	CcSEcCtD
Celecoxib—Headache—Prednisone—multiple sclerosis	2.4e-05	0.000269	CcSEcCtD
Celecoxib—Hypersensitivity—Methotrexate—multiple sclerosis	2.36e-05	0.000264	CcSEcCtD
Celecoxib—Asthenia—Methotrexate—multiple sclerosis	2.3e-05	0.000257	CcSEcCtD
Celecoxib—Nausea—Prednisone—multiple sclerosis	2.28e-05	0.000255	CcSEcCtD
Celecoxib—Pruritus—Methotrexate—multiple sclerosis	2.27e-05	0.000254	CcSEcCtD
Celecoxib—Diarrhoea—Methotrexate—multiple sclerosis	2.19e-05	0.000245	CcSEcCtD
Celecoxib—Dizziness—Methotrexate—multiple sclerosis	2.12e-05	0.000237	CcSEcCtD
Celecoxib—Vomiting—Methotrexate—multiple sclerosis	2.04e-05	0.000228	CcSEcCtD
Celecoxib—Rash—Methotrexate—multiple sclerosis	2.02e-05	0.000226	CcSEcCtD
Celecoxib—Dermatitis—Methotrexate—multiple sclerosis	2.02e-05	0.000226	CcSEcCtD
Celecoxib—Headache—Methotrexate—multiple sclerosis	2.01e-05	0.000225	CcSEcCtD
Celecoxib—Nausea—Methotrexate—multiple sclerosis	1.9e-05	0.000213	CcSEcCtD
Celecoxib—PTGS2—Spinal Cord Injury—MAPK1—multiple sclerosis	1.17e-05	0.00016	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—CYP24A1—multiple sclerosis	1.16e-05	0.000159	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—CYP27B1—multiple sclerosis	1.16e-05	0.000159	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—TLR4—multiple sclerosis	1.16e-05	0.000159	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—HLA-DRB1—multiple sclerosis	1.16e-05	0.000159	CbGpPWpGaD
Celecoxib—ALB—Folate Metabolism—IL6—multiple sclerosis	1.15e-05	0.000158	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—GPR65—multiple sclerosis	1.15e-05	0.000158	CbGpPWpGaD
Celecoxib—ALB—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	1.14e-05	0.000157	CbGpPWpGaD
Celecoxib—CA14—Metabolism—ALB—multiple sclerosis	1.14e-05	0.000156	CbGpPWpGaD
Celecoxib—ALB—Selenium Micronutrient Network—TNF—multiple sclerosis	1.14e-05	0.000156	CbGpPWpGaD
Celecoxib—CA5B—Metabolism—POMC—multiple sclerosis	1.13e-05	0.000156	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	1.13e-05	0.000155	CbGpPWpGaD
Celecoxib—PTGS2—Selenium Micronutrient Network—IL6—multiple sclerosis	1.13e-05	0.000155	CbGpPWpGaD
Celecoxib—MAPK14—Platelet activation, signaling and aggregation—TGFB1—multiple sclerosis	1.13e-05	0.000155	CbGpPWpGaD
Celecoxib—PDPK1—Hemostasis—TGFB1—multiple sclerosis	1.12e-05	0.000153	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by GPCR—POMC—multiple sclerosis	1.11e-05	0.000153	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—ICAM1—multiple sclerosis	1.11e-05	0.000152	CbGpPWpGaD
Celecoxib—PTGS2—Spinal Cord Injury—TNF—multiple sclerosis	1.11e-05	0.000152	CbGpPWpGaD
Celecoxib—CA5A—Metabolism—ALB—multiple sclerosis	1.11e-05	0.000152	CbGpPWpGaD
Celecoxib—CA6—Metabolism—ALB—multiple sclerosis	1.11e-05	0.000152	CbGpPWpGaD
Celecoxib—MAPK14—Platelet activation, signaling and aggregation—MAPK1—multiple sclerosis	1.11e-05	0.000152	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—SRM—multiple sclerosis	1.1e-05	0.000151	CbGpPWpGaD
Celecoxib—PDPK1—Hemostasis—MAPK1—multiple sclerosis	1.1e-05	0.00015	CbGpPWpGaD
Celecoxib—MAPK14—Gene Expression—PGR—multiple sclerosis	1.09e-05	0.00015	CbGpPWpGaD
Celecoxib—PDPK1—Disease—APOE—multiple sclerosis	1.09e-05	0.00015	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—SRM—multiple sclerosis	1.09e-05	0.00015	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by GPCR—CCL2—multiple sclerosis	1.09e-05	0.000149	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—CXCL10—multiple sclerosis	1.08e-05	0.000149	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—CD80—multiple sclerosis	1.07e-05	0.000147	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—CD28—multiple sclerosis	1.07e-05	0.000146	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—GPC5—multiple sclerosis	1.06e-05	0.000146	CbGpPWpGaD
Celecoxib—MAPK14—Cellular responses to stress—STAT3—multiple sclerosis	1.06e-05	0.000145	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—CXCL13—multiple sclerosis	1.05e-05	0.000144	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—CCR1—multiple sclerosis	1.05e-05	0.000144	CbGpPWpGaD
Celecoxib—CA12—Metabolism—POMC—multiple sclerosis	1.05e-05	0.000144	CbGpPWpGaD
Celecoxib—ABCC4—Hemostasis—ALB—multiple sclerosis	1.05e-05	0.000144	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—PTPRC—multiple sclerosis	1.05e-05	0.000144	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—CCR2—multiple sclerosis	1.05e-05	0.000144	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—TLR4—multiple sclerosis	1.03e-05	0.000142	CbGpPWpGaD
Celecoxib—CA5B—Metabolism—ALB—multiple sclerosis	1.03e-05	0.000142	CbGpPWpGaD
Celecoxib—CYP2D6—Biological oxidations—POMC—multiple sclerosis	1.02e-05	0.00014	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—HLA-DPB1—multiple sclerosis	1.01e-05	0.000139	CbGpPWpGaD
Celecoxib—CYP2C9—Biological oxidations—POMC—multiple sclerosis	1.01e-05	0.000139	CbGpPWpGaD
Celecoxib—MAPK14—Signaling by NGF—STAT3—multiple sclerosis	9.9e-06	0.000136	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by GPCR—TYK2—multiple sclerosis	9.89e-06	0.000136	CbGpPWpGaD
Celecoxib—PDPK1—Disease—CD80—multiple sclerosis	9.88e-06	0.000135	CbGpPWpGaD
Celecoxib—PDPK1—Innate Immune System—MAPK1—multiple sclerosis	9.88e-06	0.000135	CbGpPWpGaD
Celecoxib—CA4—Metabolism—APOE—multiple sclerosis	9.76e-06	0.000134	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—CD40—multiple sclerosis	9.76e-06	0.000134	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—ITGA4—multiple sclerosis	9.76e-06	0.000134	CbGpPWpGaD
Celecoxib—MAPK14—Cellular Senescence—IL6—multiple sclerosis	9.75e-06	0.000134	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—IFNB1—multiple sclerosis	9.68e-06	0.000133	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—ITGA4—multiple sclerosis	9.62e-06	0.000132	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—CTLA4—multiple sclerosis	9.62e-06	0.000132	CbGpPWpGaD
Celecoxib—MAPK14—Cellular responses to stress—MAPK1—multiple sclerosis	9.59e-06	0.000131	CbGpPWpGaD
Celecoxib—CA12—Metabolism—ALB—multiple sclerosis	9.58e-06	0.000131	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—CD80—multiple sclerosis	9.55e-06	0.000131	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—IFNB1—multiple sclerosis	9.55e-06	0.000131	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—CD86—multiple sclerosis	9.49e-06	0.00013	CbGpPWpGaD
Celecoxib—ALB—Metabolism—CYP27B1—multiple sclerosis	9.39e-06	0.000129	CbGpPWpGaD
Celecoxib—ALB—Metabolism—CYP24A1—multiple sclerosis	9.39e-06	0.000129	CbGpPWpGaD
Celecoxib—CA2—Metabolism—APOE—multiple sclerosis	9.35e-06	0.000128	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—CCL5—multiple sclerosis	9.34e-06	0.000128	CbGpPWpGaD
Celecoxib—MAPK14—Hemostasis—ALB—multiple sclerosis	9.19e-06	0.000126	CbGpPWpGaD
Celecoxib—ALB—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	9.18e-06	0.000126	CbGpPWpGaD
Celecoxib—ALB—Selenium Micronutrient Network—IL6—multiple sclerosis	9.17e-06	0.000126	CbGpPWpGaD
Celecoxib—MAPK14—Developmental Biology—TYK2—multiple sclerosis	9.13e-06	0.000125	CbGpPWpGaD
Celecoxib—ABCC4—Transmembrane transport of small molecules—ALB—multiple sclerosis	9.09e-06	0.000125	CbGpPWpGaD
Celecoxib—PDPK1—GPCR downstream signaling—IL2—multiple sclerosis	9.06e-06	0.000124	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—TYK2—multiple sclerosis	9.04e-06	0.000124	CbGpPWpGaD
Celecoxib—MAPK14—Signaling by NGF—MAPK1—multiple sclerosis	9e-06	0.000123	CbGpPWpGaD
Celecoxib—MAPK14—NGF signalling via TRKA from the plasma membrane—IL6—multiple sclerosis	8.99e-06	0.000123	CbGpPWpGaD
Celecoxib—PTGS2—Spinal Cord Injury—IL6—multiple sclerosis	8.97e-06	0.000123	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—RRM1—multiple sclerosis	8.8e-06	0.000121	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—SPP1—multiple sclerosis	8.65e-06	0.000119	CbGpPWpGaD
Celecoxib—ALB—Metabolism—GPC5—multiple sclerosis	8.59e-06	0.000118	CbGpPWpGaD
Celecoxib—ABCC4—Hemostasis—IL2—multiple sclerosis	8.51e-06	0.000117	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—VCAM1—multiple sclerosis	8.49e-06	0.000116	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—HLA-DQA1—multiple sclerosis	8.47e-06	0.000116	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—IFNG—multiple sclerosis	8.46e-06	0.000116	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—CCR5—multiple sclerosis	8.41e-06	0.000115	CbGpPWpGaD
Celecoxib—CA4—Metabolism—POMC—multiple sclerosis	8.38e-06	0.000115	CbGpPWpGaD
Celecoxib—PDPK1—Disease—TYK2—multiple sclerosis	8.34e-06	0.000114	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—IL2RA—multiple sclerosis	8.29e-06	0.000114	CbGpPWpGaD
Celecoxib—PTGS2—Disease—RPL5—multiple sclerosis	8.24e-06	0.000113	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by GPCR—IL2—multiple sclerosis	8.23e-06	0.000113	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—CD4—multiple sclerosis	8.17e-06	0.000112	CbGpPWpGaD
Celecoxib—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—multiple sclerosis	8.12e-06	0.000111	CbGpPWpGaD
Celecoxib—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—multiple sclerosis	8.1e-06	0.000111	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—TYK2—multiple sclerosis	8.06e-06	0.000111	CbGpPWpGaD
Celecoxib—CA2—Metabolism—POMC—multiple sclerosis	8.04e-06	0.00011	CbGpPWpGaD
Celecoxib—PTGS2—Integrated Pancreatic Cancer Pathway—MAPK1—multiple sclerosis	7.94e-06	0.000109	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—HLA-DQB1—multiple sclerosis	7.92e-06	0.000109	CbGpPWpGaD
Celecoxib—PTGS2—Disease—SLC11A1—multiple sclerosis	7.89e-06	0.000108	CbGpPWpGaD
Celecoxib—CA9—Metabolism—APOE—multiple sclerosis	7.88e-06	0.000108	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—CYP24A1—multiple sclerosis	7.75e-06	0.000106	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—CYP27B1—multiple sclerosis	7.75e-06	0.000106	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—CYP24A1—multiple sclerosis	7.69e-06	0.000105	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—CYP27B1—multiple sclerosis	7.69e-06	0.000105	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—APOE—multiple sclerosis	7.65e-06	0.000105	CbGpPWpGaD
Celecoxib—MAPK14—Gene Expression—VDR—multiple sclerosis	7.64e-06	0.000105	CbGpPWpGaD
Celecoxib—CA4—Metabolism—ALB—multiple sclerosis	7.64e-06	0.000105	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—CD86—multiple sclerosis	7.62e-06	0.000105	CbGpPWpGaD
Celecoxib—PDPK1—Innate Immune System—IL6—multiple sclerosis	7.59e-06	0.000104	CbGpPWpGaD
Celecoxib—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—multiple sclerosis	7.56e-06	0.000104	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—IL1B—multiple sclerosis	7.55e-06	0.000103	CbGpPWpGaD
Celecoxib—PDPK1—Disease—CD4—multiple sclerosis	7.54e-06	0.000103	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—IL2—multiple sclerosis	7.52e-06	0.000103	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	7.51e-06	0.000103	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—CCL3—multiple sclerosis	7.5e-06	0.000103	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—CD40LG—multiple sclerosis	7.48e-06	0.000103	CbGpPWpGaD
Celecoxib—ALB—Platelet activation, signaling and aggregation—IL2—multiple sclerosis	7.47e-06	0.000102	CbGpPWpGaD
Celecoxib—MAPK14—Hemostasis—IL2—multiple sclerosis	7.45e-06	0.000102	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—CD8A—multiple sclerosis	7.39e-06	0.000101	CbGpPWpGaD
Celecoxib—MAPK14—Cellular responses to stress—IL6—multiple sclerosis	7.37e-06	0.000101	CbGpPWpGaD
Celecoxib—CA2—Metabolism—ALB—multiple sclerosis	7.33e-06	0.0001	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—CD4—multiple sclerosis	7.29e-06	9.99e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—PTGER4—multiple sclerosis	7.22e-06	9.9e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—SRM—multiple sclerosis	7.19e-06	9.86e-05	CbGpPWpGaD
Celecoxib—MAPK14—Developmental Biology—MMP9—multiple sclerosis	7.19e-06	9.86e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—RRM1—multiple sclerosis	7.12e-06	9.75e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—HLA-B—multiple sclerosis	7.11e-06	9.75e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—PGR—multiple sclerosis	7.11e-06	9.75e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—GPC5—multiple sclerosis	7.09e-06	9.72e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—GPC5—multiple sclerosis	7.03e-06	9.64e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—CXCR3—multiple sclerosis	6.97e-06	9.56e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—CD80—multiple sclerosis	6.92e-06	9.49e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling by NGF—IL6—multiple sclerosis	6.91e-06	9.48e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—CD28—multiple sclerosis	6.91e-06	9.47e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	6.82e-06	9.35e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—CCR2—multiple sclerosis	6.78e-06	9.3e-05	CbGpPWpGaD
Celecoxib—CA9—Metabolism—POMC—multiple sclerosis	6.77e-06	9.28e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Biological oxidations—POMC—multiple sclerosis	6.67e-06	9.14e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—IL2RA—multiple sclerosis	6.66e-06	9.14e-05	CbGpPWpGaD
Celecoxib—ABCC4—Hemostasis—TGFB1—multiple sclerosis	6.64e-06	9.1e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—HLA-A—multiple sclerosis	6.59e-06	9.03e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—POMC—multiple sclerosis	6.58e-06	9.01e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—IL2RA—multiple sclerosis	6.57e-06	9.01e-05	CbGpPWpGaD
Celecoxib—ABCC4—Hemostasis—MAPK1—multiple sclerosis	6.51e-06	8.92e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—CCL2—multiple sclerosis	6.43e-06	8.82e-05	CbGpPWpGaD
Celecoxib—MAPK14—Developmental Biology—STAT3—multiple sclerosis	6.39e-06	8.76e-05	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—STAT3—multiple sclerosis	6.33e-06	8.67e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—CD28—multiple sclerosis	6.3e-06	8.64e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by GPCR—MAPK1—multiple sclerosis	6.29e-06	8.63e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—CNR1—multiple sclerosis	6.26e-06	8.58e-05	CbGpPWpGaD
Celecoxib—CA9—Metabolism—ALB—multiple sclerosis	6.17e-06	8.46e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—TLR4—multiple sclerosis	6.03e-06	8.26e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—HLA-DRB1—multiple sclerosis	6.02e-06	8.25e-05	CbGpPWpGaD
Celecoxib—MAPK14—Developmental Biology—TGFB1—multiple sclerosis	5.93e-06	8.12e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—RRM1—multiple sclerosis	5.88e-06	8.05e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	5.86e-06	8.04e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—TYK2—multiple sclerosis	5.84e-06	8.01e-05	CbGpPWpGaD
Celecoxib—PDPK1—Disease—STAT3—multiple sclerosis	5.84e-06	8.01e-05	CbGpPWpGaD
Celecoxib—ALB—Platelet activation, signaling and aggregation—TGFB1—multiple sclerosis	5.83e-06	7.99e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—RRM1—multiple sclerosis	5.82e-06	7.98e-05	CbGpPWpGaD
Celecoxib—MAPK14—Hemostasis—TGFB1—multiple sclerosis	5.81e-06	7.97e-05	CbGpPWpGaD
Celecoxib—MAPK14—Developmental Biology—MAPK1—multiple sclerosis	5.81e-06	7.97e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—ICAM1—multiple sclerosis	5.78e-06	7.92e-05	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—MAPK1—multiple sclerosis	5.75e-06	7.88e-05	CbGpPWpGaD
Celecoxib—ALB—Platelet activation, signaling and aggregation—MAPK1—multiple sclerosis	5.72e-06	7.83e-05	CbGpPWpGaD
Celecoxib—MAPK14—Hemostasis—MAPK1—multiple sclerosis	5.7e-06	7.81e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—CXCL10—multiple sclerosis	5.64e-06	7.73e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—CD80—multiple sclerosis	5.56e-06	7.63e-05	CbGpPWpGaD
Celecoxib—MAPK14—Developmental Biology—TNF—multiple sclerosis	5.53e-06	7.58e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	5.52e-06	7.57e-05	CbGpPWpGaD
Celecoxib—PDPK1—Disease—MYC—multiple sclerosis	5.43e-06	7.44e-05	CbGpPWpGaD
Celecoxib—PDPK1—Disease—TGFB1—multiple sclerosis	5.41e-06	7.42e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	5.34e-06	7.33e-05	CbGpPWpGaD
Celecoxib—PDPK1—Disease—MAPK1—multiple sclerosis	5.31e-06	7.28e-05	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—MAPK1—multiple sclerosis	5.13e-06	7.03e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—CYP24A1—multiple sclerosis	5.07e-06	6.95e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—CYP27B1—multiple sclerosis	5.07e-06	6.95e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—BCHE—multiple sclerosis	5.05e-06	6.93e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—CD86—multiple sclerosis	4.93e-06	6.76e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—IL2—multiple sclerosis	4.86e-06	6.66e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—CCL5—multiple sclerosis	4.85e-06	6.65e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by GPCR—IL6—multiple sclerosis	4.84e-06	6.63e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	4.74e-06	6.5e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—TYK2—multiple sclerosis	4.7e-06	6.44e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—GPC5—multiple sclerosis	4.64e-06	6.36e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—MMP9—multiple sclerosis	4.6e-06	6.31e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	4.52e-06	6.19e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—CD86—multiple sclerosis	4.5e-06	6.17e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—SPP1—multiple sclerosis	4.49e-06	6.16e-05	CbGpPWpGaD
Celecoxib—MAPK14—Developmental Biology—IL6—multiple sclerosis	4.46e-06	6.12e-05	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—IL6—multiple sclerosis	4.42e-06	6.06e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—IFNG—multiple sclerosis	4.4e-06	6.03e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—CCR5—multiple sclerosis	4.37e-06	5.99e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—IL2RA—multiple sclerosis	4.31e-06	5.91e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—CD4—multiple sclerosis	4.25e-06	5.82e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—STAT3—multiple sclerosis	4.09e-06	5.61e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—BCHE—multiple sclerosis	4.09e-06	5.6e-05	CbGpPWpGaD
Celecoxib—PDPK1—Disease—IL6—multiple sclerosis	4.08e-06	5.59e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—CCR5—multiple sclerosis	3.99e-06	5.47e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—APOE—multiple sclerosis	3.98e-06	5.45e-05	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—IL6—multiple sclerosis	3.94e-06	5.41e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—IL1B—multiple sclerosis	3.92e-06	5.38e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—IL2—multiple sclerosis	3.91e-06	5.36e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—HLA-A—multiple sclerosis	3.89e-06	5.33e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	3.88e-06	5.32e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—IL2—multiple sclerosis	3.85e-06	5.28e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—RRM1—multiple sclerosis	3.84e-06	5.27e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—MYC—multiple sclerosis	3.8e-06	5.21e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—TGFB1—multiple sclerosis	3.79e-06	5.2e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—MAPK1—multiple sclerosis	3.72e-06	5.1e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—APOE—multiple sclerosis	3.63e-06	4.97e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—CD80—multiple sclerosis	3.6e-06	4.93e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	3.54e-06	4.85e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—POMC—multiple sclerosis	3.42e-06	4.68e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—BCHE—multiple sclerosis	3.37e-06	4.63e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—BCHE—multiple sclerosis	3.35e-06	4.59e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—CCL2—multiple sclerosis	3.34e-06	4.58e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—STAT3—multiple sclerosis	3.29e-06	4.51e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—CD80—multiple sclerosis	3.28e-06	4.5e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—APOE—multiple sclerosis	3.04e-06	4.17e-05	CbGpPWpGaD
Celecoxib—MAPK14—Gene Expression—MYC—multiple sclerosis	3.04e-06	4.16e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—TYK2—multiple sclerosis	3.04e-06	4.16e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—TGFB1—multiple sclerosis	3e-06	4.12e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—MAPK1—multiple sclerosis	2.99e-06	4.1e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—MAPK1—multiple sclerosis	2.95e-06	4.04e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—IL6—multiple sclerosis	2.86e-06	3.92e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—TYK2—multiple sclerosis	2.77e-06	3.8e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—POMC—multiple sclerosis	2.61e-06	3.58e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—IL2—multiple sclerosis	2.53e-06	3.46e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—CD4—multiple sclerosis	2.5e-06	3.43e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—APOE—multiple sclerosis	2.46e-06	3.37e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—MMP9—multiple sclerosis	2.39e-06	3.28e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—ALB—multiple sclerosis	2.38e-06	3.26e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—IL6—multiple sclerosis	2.3e-06	3.15e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—BCHE—multiple sclerosis	2.21e-06	3.02e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—STAT3—multiple sclerosis	2.13e-06	2.91e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—POMC—multiple sclerosis	2.11e-06	2.9e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—APOE—multiple sclerosis	2.03e-06	2.78e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—APOE—multiple sclerosis	2.01e-06	2.76e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—MYC—multiple sclerosis	1.98e-06	2.71e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—TGFB1—multiple sclerosis	1.97e-06	2.7e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—STAT3—multiple sclerosis	1.94e-06	2.66e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—MAPK1—multiple sclerosis	1.93e-06	2.65e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—MYC—multiple sclerosis	1.8e-06	2.47e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—TGFB1—multiple sclerosis	1.8e-06	2.46e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—MAPK1—multiple sclerosis	1.76e-06	2.42e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—POMC—multiple sclerosis	1.74e-06	2.39e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—POMC—multiple sclerosis	1.73e-06	2.37e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—ALB—multiple sclerosis	1.59e-06	2.18e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—ALB—multiple sclerosis	1.58e-06	2.16e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—IL6—multiple sclerosis	1.48e-06	2.04e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—IL6—multiple sclerosis	1.35e-06	1.86e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—APOE—multiple sclerosis	1.33e-06	1.82e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—POMC—multiple sclerosis	1.14e-06	1.56e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—ALB—multiple sclerosis	1.04e-06	1.43e-05	CbGpPWpGaD
